Literature DB >> 20571940

Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer.

Usha Agrawal1, Ashwani K Mishra, Payal Salgia, Saurabh Verma, Nayan K Mohanty, Sunita Saxena.   

Abstract

Non muscle invasive bladder cancers recur frequently and identification of biomarkers for predicting recurrence are necessary. The present study evaluated the individual and synergistic effects of tumor suppressor (p53/p21waf1) and angiogenesis [vascular endothelial growth factor (VEGF)/endoglin (CD105)] markers. The study included 90 cases of non muscle invasive bladder cancer. Cell spots were stained with primary antibodies and Flourescein isothiocyanate (FITC). Slides were observed under confocal laser scanning microscope for protein expression. The association between the markers individually and synergistically with recurrence were assessed by a χ2 and Fisher's Exact test. Survival analysis was performed to predict recurrence and test for significant difference in recurrence free survival probability. Recurrence [overall:39(43.3%) and low grade(LG):26(54.2%)] was significant with p53 and VEGF expression and the profiles p53/VEGF, p53/CD105, VEGF/CD105, p53/p21/CD105, p53/VEGF/CD105 and all four were significantly associated with recurrence in both groups. In the multivariable model the [HR(95%CI),p: overall and LG] profiles p21/VEGF [2.195(1.052-4.582),0.036; 3.425(1.332-8.811),0.011], VEGF/CD105[2.624(1.274-5.403),0.009 and 3.380(1.348-8.472),0.009], p53/p21/CD105 [2.000(0.993-4.027),0.052 and 2.539(1.047-6.157),0.039], p53/VEGF/CD105 [2.360(1.148-4.849),0.020 and 2.738(1.104-6.788),0.030], p21/VEGF/CD105 [2.611(1.189-5.731),0.017 and 3.946(1.530-10.182),0.005] and all four [2.382(1.021-5.556),0.045 and 3.572(1.287-9.911),0.014] significantly predicted the recurrence along with significant log rank. In the pTa subset (n = 33) the profiles p53/p21, p53/CD105, p21/VEGF, VEGF/CD105, p53/VEGF/CD105, p53/p21/CD105 and p21/VEGF/CD105, significantly predicted hazard for recurrence. The present study emphasizes an underlying association between tumor suppressor (p21waf1) and angiogenesis (VEGF/CD105) biomarkers. In addition combination profiles appeared to indicate an aggressive nature with high propensity for recurrence in LG and pTa tumours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571940     DOI: 10.1007/s12253-010-9287-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

1.  Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer.

Authors:  C Mian; M Lodde; E Comploj; L Lusuardi; S Palermo; M Mian; K Maier; A Pycha
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Regulation of p21WAF1/CIP1 expression by p53-independent pathways.

Authors:  Y X Zeng; W S el-Deiry
Journal:  Oncogene       Date:  1996-04-04       Impact factor: 9.867

3.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

4.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.

Authors:  Reda S Saad; Yulin L Liu; Girija Nathan; James Celebrezze; David Medich; Jan F Silverman
Journal:  Mod Pathol       Date:  2004-02       Impact factor: 7.842

Review 5.  CD105 is important for angiogenesis: evidence and potential applications.

Authors:  Sarah E Duff; Chenggang Li; John M Garland; Shant Kumar
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

6.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.

Authors:  Yasser M El-Gohary; Jan F Silverman; Peter R Olson; Yulin L Liu; Jeffrey K Cohen; Ralph Miller; Reda S Saad
Journal:  Am J Clin Pathol       Date:  2007-04       Impact factor: 2.493

7.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

8.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.

Authors:  J P Stein; D A Ginsberg; G D Grossfeld; S J Chatterjee; D Esrig; M G Dickinson; S Groshen; C R Taylor; P A Jones; D G Skinner; R J Cote
Journal:  J Natl Cancer Inst       Date:  1998-07-15       Impact factor: 13.506

9.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

10.  Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder.

Authors:  N K Mohanty; Rajiba L Nayak; Pawan Vasudeva; R P Arora
Journal:  Indian J Urol       Date:  2008-01
View more
  6 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladder.

Authors:  Ken-Ichi Harada; Hideaki Miyake; Tomoaki Terakawa; Masato Fujisawa
Journal:  Curr Urol       Date:  2012-04-30

3.  Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma.

Authors:  Xin Ning; Yaoliang Deng
Journal:  Onco Targets Ther       Date:  2017-03-20       Impact factor: 4.147

4.  HIF-1, GLUT1, endoglin, and BIRC5 expression in urine samples obtained from patients with bladder malignancies - after photodynamic diagnosis (PDD).

Authors:  Michał Markowski; Marek Lipiński; Anna Krzeslak; Ewa Forma; Magdalena Bryś; Waldemar Różański
Journal:  Cent European J Urol       Date:  2012-09-04

5.  TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population.

Authors:  Xiao Yang; Pengchao Li; Xuejian Yang; Chao Qin; Qiang Cao; Zhengdong Zhang; Meilin Wang; Hongzhou Cai; Jinbao Gu; Jun Tao; Min Gu; Qiang Lu; Changjun Yin
Journal:  Int J Genomics       Date:  2013-12-03       Impact factor: 2.326

6.  A molecular signature for anastasis, recovery from the brink of apoptotic cell death.

Authors:  Gongping Sun; Elmer Guzman; Varuzhan Balasanyan; Christopher M Conner; Kirsten Wong; Hongjun Robin Zhou; Kenneth S Kosik; Denise J Montell
Journal:  J Cell Biol       Date:  2017-08-02       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.